<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02092168</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-105</org_study_id>
    <nct_id>NCT02092168</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects</brief_title>
  <official_title>Single-dose and Steady-state Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects Compared With Those in Healthy Male Young Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of age on the pharmacokinetic (PK)
      profile of BIA 9-1067 and its metabolites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology:

      Single-centre, open-label, parallel group, non-randomised multiple-dose 7-day study in 12
      healthy elderly and 12 healthy younger male subjects.

      Duration of treatment:

      Each subject participated in the study for approximately 6 weeks. Participation included a
      screening evaluation within 28 days before inpatient period, a 12 day inpatient period and an
      end of study visit (ESV) 7 to 10 days after the discharge from the Unit.

      The study design followed the recommendations of the CPMP/ICH/379/95 (ICH Topic E7) Note for
      Guidance on Studies in Support of Special Populations: Geriatrics, namely in the inclusion of
      subjects aged 65 years or older and contemplating single-dose and steady-state PK profiles.
      As the primary endpoint of the study was to characterize the pharmacokinetic profile of BIA
      9-1067 and its metabolites in different parallel groups, there was no need to implement
      blinding procedures or to include a control group. Consequently, the trial was an open label
      study. Healthy subjects rather than patients with Parkinson's disease have been chosen as the
      study population, due to the lack of over-toxicity of the drug and an acceptable risk-benefit
      ratio. This allowed for a better interpretation of the study results, as there were no
      confounding factors resulting from changes in disease state and or concomitant medications.

      The subjects were given a screening number after signing the informed consent by
      chronological order of inclusion in each group (young/elderly).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Plasma Concentration</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Cmax (BIA 9-1067) - maximum plasma concentration of BIA 9-1067</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - Time to Reach Cmax</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>Tmax - Time to reach maximum plasma concentration of BIA 9-1067</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to Last Observed Concentration</measure>
    <time_frame>Day 1 and Day 7</time_frame>
    <description>AUC0-t - Area under the plasma concentration-time curve of BIA 9-1067 from time 0 to last observed concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>BIA 9-1067 30 mg (once daily) - Elderly Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 30 mg (once daily) - Young Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <arm_group_label>BIA 9-1067 30 mg (once daily) - Elderly Subjects</arm_group_label>
    <arm_group_label>BIA 9-1067 30 mg (once daily) - Young Subjects</arm_group_label>
    <other_name>Opicapone, OPC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects (young and elderly):

          1. A signed and dated informed consent form before any study-specific screening procedure
             is performed.

          2. Healthy as determined by the investigator on the basis of medical history, physical
             examination, clinical laboratory test results, vital signs and digital 12-lead
             electrocardiogram (ECG).

          3. Non-smoker or smoker of fewer than 10 cigarettes per day as determined by history. Had
             to be able to abstain from smoking during the inpatient stay.

          4. With a body mass index (BMI) between 19 and 30 kg/m2, inclusive.

             Young subjects only:

          5. Males aged between 18 and 40 years, inclusive.

             Elderly subjects only:

          6. Males older than 65 years, inclusive.

        Exclusion Criteria:

        All subjects (young and elderly):

        General

          1. Subjects who had participated in a clinical trial with an investigational drug within
             the 90 days prior to screening.

          2. Subjects who were likely to be noncompliant with the protocol, or who were felt to be
             unsuitable by the Investigator for any other reason.

          3. Positive serologic findings for human immunodeficiency virus (HIV) antibodies,
             hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies.

          4. Positive findings of urine drug screen (amphetamines, barbiturates, benzodiazepines,
             cannabinoids, cocaine, methadone, opiates, MDMA [3,4-ethylenedioxymethamphetamine;
             ecstasy]).

             Medical History

          5. Any significant cardiovascular, hepatic, renal, respiratory (e.g. childhood asthma),
             gastrointestinal, endocrine (e.g. diabetes,), immunological, dermatological,
             haematological, neurological, or psychiatric disease and history thereof.

          6. Acute disease state (e.g., nausea, vomiting, fever, diarrhoea) within 7 days before
             study Day 1.

          7. History of drug abuse within 1 year before study Day 1.

          8. History of alcoholism within 1 year before Day 1. Consumption of more than 50 g of
             ethanol per day (12.5 cL glass of 10° [10%] wine = 12 g; 4 cL of aperitif, 42° [42%]
             whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15
             g).

          9. History of any clinically important drug allergy.

         10. Had previously received BIA 9-1067.

             Prohibited treatments and dietary restrictions

         11. Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or
             soda) in excess of 6 cups per day (or equivalent), of grapefruit,
             grapefruit-containing products, or alcoholic beverages within 24 hours before study
             Day 1.

         12. Use of any over-the-counter drugs including herbal supplements (except for the
             occasional use of acetaminophen [paracetamol], aspirin and vitamins ≤100% recommended
             daily allowance) within 7 days before IMP administration.

         13. Donation of blood (i.e. 450 ml) within 60 days before study Day 1.

             Young subjects only:

             Prohibited treatments and dietary restrictions

         14. Prohibited Treatments: use of any investigational drug within 90 days (young and
             elderly subjects) or prescription drug within 30 days before investigational medical
             product (IMP) administration.

             Elderly subjects only:

             Prohibited treatments and dietary restrictions

         15. For elderly subjects, previously prescribed medications that do not interfere with
             absorption, distribution, metabolism, and excretion or safety/tolerability evaluation
             of BIA 9-1067 and adrenal or renal function were allowed if the dose regimen had been
             stable for at least 4 weeks and was expected to remain stable throughout the study.
             Such concomitant medications was reviewed and mutually agreed upon by the sponsor and
             the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrício SOARES-DA-SILVA, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BIAL - Portela &amp; Ca S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BIOTRIAL</name>
      <address>
        <city>Rueil</city>
        <state>Malmaison</state>
        <zip>F-92501</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2012</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <results_first_submitted>January 7, 2015</results_first_submitted>
  <results_first_submitted_qc>January 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2015</results_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opicapone</keyword>
  <keyword>BIAL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opicapone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIA 9-1067 30 mg (QD) - Elderly Subjects</title>
          <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
BIA 9-1067 30 mg (QD) - Elderly Subjects</description>
        </group>
        <group group_id="P2">
          <title>BIA 9-1067 30 mg (QD) - Young Subjects</title>
          <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
BIA 9-1067 30 mg (QD) - Young Subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BIA 9-1067 30 mg (Once Daily) - Elderly Subjects</title>
          <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
BIA 9-1067 30 mg (once daily) - Elderly Subjects</description>
        </group>
        <group group_id="B2">
          <title>BIA 9-1067 30 mg (Once Daily) - Young Subjects</title>
          <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
BIA 9-1067 30 mg (once daily) - Young Subjects</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Plasma Concentration</title>
        <description>Cmax (BIA 9-1067) - maximum plasma concentration of BIA 9-1067</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 30 mg (Once Daily) - Elderly Subjects</title>
            <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
BIA 9-1067 30 mg (once daily) - Elderly Subjects</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 30 mg (Once Daily) - Young Subjects</title>
            <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
BIA 9-1067 30 mg (once daily) - Young Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Plasma Concentration</title>
          <description>Cmax (BIA 9-1067) - maximum plasma concentration of BIA 9-1067</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407.4" spread="81.1"/>
                    <measurement group_id="O2" value="391.1" spread="138.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439.6" spread="127.5"/>
                    <measurement group_id="O2" value="382.0" spread="146.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - Time to Reach Cmax</title>
        <description>Tmax - Time to reach maximum plasma concentration of BIA 9-1067</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 30 mg (Once Daily) - Elderly Subjects</title>
            <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
BIA 9-1067 30 mg (once daily) - Elderly Subjects</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 30 mg (Once Daily) - Young Subjects</title>
            <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
BIA 9-1067 30 mg (once daily) - Young Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time to Reach Cmax</title>
          <description>Tmax - Time to reach maximum plasma concentration of BIA 9-1067</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.2" lower_limit="0.5" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.5" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.7" lower_limit="1.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to Last Observed Concentration</title>
        <description>AUC0-t - Area under the plasma concentration-time curve of BIA 9-1067 from time 0 to last observed concentration</description>
        <time_frame>Day 1 and Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 30 mg (Once Daily) - Elderly Subjects</title>
            <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
BIA 9-1067 30 mg (once daily) - Elderly Subjects</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 30 mg (Once Daily) - Young Subjects</title>
            <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
BIA 9-1067 30 mg (once daily) - Young Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - Area Under the Plasma Concentration-time Curve From Time 0 to Last Observed Concentration</title>
          <description>AUC0-t - Area under the plasma concentration-time curve of BIA 9-1067 from time 0 to last observed concentration</description>
          <units>ng.h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1265.9" spread="240.6"/>
                    <measurement group_id="O2" value="1204.1" spread="474.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1413.65" spread="451.3"/>
                    <measurement group_id="O2" value="1112.3" spread="338.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BIA 9-1067 30 mg (Once Daily) - Elderly Subjects</title>
          <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
BIA 9-1067 30 mg (once daily) - Elderly Subjects</description>
        </group>
        <group group_id="E2">
          <title>BIA 9-1067 30 mg (Once Daily) - Young Subjects</title>
          <description>BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
BIA 9-1067 30 mg (once daily) - Young Subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

